geranylgeranylacetone and Osteoporosis

geranylgeranylacetone has been researched along with Osteoporosis* in 2 studies

Reviews

2 review(s) available for geranylgeranylacetone and Osteoporosis

Article	Year
[Effects of biologic therapies on systemic osteoporosis in patients with rheumatoid arthritis]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:5 Biologic therapies including tumor necrosis factor alpha (TNF-alpha)-blocking therapy have been shown to reduce disease activity measures and joint damage progression. However, effects of biologic therapies on systemic osteoporosis remain to be elucidated in patients with rheumatoid arthritis (RA). In this review article, we reviewed the literature on the issue after we described our hypothesis on the pathogenesis of synovitis in patients with RA. Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Denosumab; Diterpenes; Drug Design; Humans; Infliximab; Interleukin-1; Interleukin-17; Interleukin-6; Osteoclasts; Osteoporosis; RANK Ligand; Receptors, Interleukin-6; Tumor Necrosis Factor-alpha	2009
[Geranylgeranylacetone, an antiulcer drug, potently inhibits formation and function of human osteoclasts in vitro and bone loss in ovariectomized rats]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Animals; Anti-Ulcer Agents; Bone Density; Cell Differentiation; Diterpenes; Drug Design; Estrogens; Humans; Osteoclasts; Osteoporosis; Ovariectomy; Polyisoprenyl Phosphates	2004

Article

Year

[Effects of biologic therapies on systemic osteoporosis in patients with rheumatoid arthritis].

Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:5

Biologic therapies including tumor necrosis factor alpha (TNF-alpha)-blocking therapy have been shown to reduce disease activity measures and joint damage progression. However, effects of biologic therapies on systemic osteoporosis remain to be elucidated in patients with rheumatoid arthritis (RA). In this review article, we reviewed the literature on the issue after we described our hypothesis on the pathogenesis of synovitis in patients with RA.

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Denosumab; Diterpenes; Drug Design; Humans; Infliximab; Interleukin-1; Interleukin-17; Interleukin-6; Osteoclasts; Osteoporosis; RANK Ligand; Receptors, Interleukin-6; Tumor Necrosis Factor-alpha

2009

[Geranylgeranylacetone, an antiulcer drug, potently inhibits formation and function of human osteoclasts in vitro and bone loss in ovariectomized rats].

Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2

Topics: Animals; Anti-Ulcer Agents; Bone Density; Cell Differentiation; Diterpenes; Drug Design; Estrogens; Humans; Osteoclasts; Osteoporosis; Ovariectomy; Polyisoprenyl Phosphates

2004